Methylation analysis and diagnostics of Beckwith-Wiedemann syndrome in 1,000 subjects by Ibrahim, Abdulla et al.
Ibrahim et al. Clinical Epigenetics 2014, 6:11
http://www.clinicalepigeneticsjournal.com/content/6/1/11RESEARCH Open AccessMethylation analysis and diagnostics of
Beckwith-Wiedemann syndrome in 1,000 subjects
Abdulla Ibrahim1,2, Gail Kirby3, Carol Hardy4, Renuka P Dias3, Louise Tee3, Derek Lim3,4, Jonathan Berg2,
Fiona MacDonald4, Peter Nightingale5 and Eamonn R Maher1,3*Abstract
Background: Beckwith-Wiedemann syndrome (BWS), a congenital overgrowth disorder with variable expressivity
and a predisposition to tumorigenesis, results from disordered expression and/or function of imprinted genes at
chromosome 11p15.5. There are no generally agreed clinical diagnostic criteria, with molecular studies commonly
performed to confirm diagnosis. In particular, methylation status analysis at two 11p15.5 imprinting control centres
(IC1 and IC2) detects up to 80% of BWS cases (though low-level mosaicism may not be detected). In order to
evaluate the relationship between the clinical presentation of suspected BWS and IC1/2 methylation abnormalities
we reviewed the results of >1,000 referrals for molecular diagnostic testing.
Results: Out of 1,091 referrals, 507 (46.5%) had a positive diagnostic test for BWS. The frequency of tumours was
3.4% in those with a molecular diagnosis of BWS. Previously reported genotype-phenotype associations with
paternal uniparental disomy, IC1, and IC2 epimutation groups were confirmed and potential novel associations
detected. Predictive values of previously described clinical diagnostic criteria were compared and, although there
were differences in their sensitivity and specificity, receiver operating characteristic (ROC) analysis demonstrated
that these were not optimal in predicting 11p15.5 methylation abnormalities. Using logistic regression, we identified
clinical features with the best predictive value for a positive methylation abnormality. Furthermore, we developed a
weighted scoring system (sensitivity 75.9%, and specificity 81.8%) to prioritise patients presenting with the most
common features of BWS, and ROC analysis demonstrated superior performance (area under the curve 0.85, 95% CI
0.83 to 0.87) compared to previous criteria.
Conclusions: We suggest that this novel tool will facilitate selection of patients with suspected BWS for routine
diagnostic testing and so improve the diagnosis of the disorder.
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Beckwith-Wiedemann syndrome (BWS; MIM #130650),
a congenital overgrowth disorder with a predisposition
toward tumorigenesis, results from abnormal expression/
function of imprinted genes from the chromosome 11p15.5
imprinted gene cluster [1-4]. Only a minority of human
genes (around 100) are imprinted (that is, epigenetically
regulated such that one allele is preferentially expressed* Correspondence: erm1000@medschl.cam.ac.uk
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unless otherwise stated.according to the parent-of-origin of the allele) but im-
printed genes characteristically occur in clusters and, to
date, appear to be preferentially implicated in prenatal
growth and development [5,6]. Since the first clinical
description of BWS 60 years ago [7,8] there have
been considerable advances in defining the molecular
basis of this disorder (see [1-4] and references within). It
is now recognised that increased IGF2 expression and/or
loss of expression or inactivation of CDKN1C account for
most cases of this disorder. Disordered IGF2/CDKN1C
function may be caused by multiple mechanisms, including
paternal uniparental disomy (pUPD), cytogenetic ab-
normalities (such as paternally inherited duplicationsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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versions), imprinting centre (IC) mutations/deletions and
epimutations, and CDKN1C mutations (see [1-4] and ref-
erences within). Despite the marked heterogeneity of
possible epigenetic/genetic mechanisms, most cases of
BWS are sporadic and result from pUPD or IC epimu-
tations, and diagnostic investigation for suspected BWS
typically involves methylation analysis at two differen-
tially methylated regions (H19/IGF2 intergenic DMR
and KvDMR1) that are coincident with the distal and
centromeric imprinting centres (IC1 and IC2, respectively)
[6,9-11]. Thus, approximately 5 to 10% of children with
BWS have a gain of methylation on the maternal IC1
allele (normally only the paternal allele is methylated),
which is associated with biallelic expression of IGF2 and
silencing of H19 expression (normally IGF2 is mono-
allelically expressed from the paternal allele and H19 is
expressed from the maternal allele only). A further
50% of individuals with BWS have a loss of methylation
at IC2 (KvDMR1); usually the paternal IC2 allele is
unmethylated and the maternal allele is methylated, but in
these cases both alleles are unmethylated [11,12]. Such
IC2 epimutations are associated with loss of function
of the CDKN1C growth suppressor. Thus, CDKN1C
is imprinted and preferentially expressed from the mater-
nal allele, and a loss of maternal allele methylation at IC2
is associated with loss of maternal allele CDKN1C expres-
sion and hence a marked reduction in CDKN1C growth
suppressor activity [13]. Whilst the frequency of CDKN1C
mutations is small (approximately 5%) in sporadic cases,
mutations may be detected in about 50% of familial
BWS cases [14,15].
Though a number of different schemes have been sug-
gested for the clinical diagnosis of BWS [16-20], there
are no generally agreed criteria. Recently, molecular gen-
etic diagnostic techniques have assumed an important
role in facilitating the diagnosis of BWS. In particular,
methylation profiling at IC1 and IC2 enables identifica-
tion of individuals with the most frequent causes of
BWS (pUPD, IC1, and IC2 epimutations) [10]. However,
low-level mosaicism, as is often the case in pUPD,
may not be detected by some methods of methylation
analysis [21]. Given the high risk of tumorigenesis in
this pUPD subgroup (24% by age 5 years) [12], identifying
these patients is important in order to better manage their
condition. Here, we have evaluated the clinical and mo-
lecular findings of >1,000 patients with suspected BWS
referred to a tertiary molecular genetics laboratory for IC1
and IC2 methylation profiling. We analysed (a) the clinical
features of different BWS molecular subgroups, (b) the
frequency of positive molecular results according to
different proposed diagnostic criteria, and (c) which of the
common clinical features were most predictive of an
abnormal IC1/2 methylation profile.Results
Clinical features of patients referred for diagnostic testing
A total of 1,091 individuals (male:female = 1.06:1) were
referred for diagnostic testing. The most frequent in-
dications for referral were: macroglossia (52.3%), anterior
abdominal wall defects (44.8%; exomphalos in 22.8%,
umbilical hernia in 21.5%, and diastasis recti in 5.4%),
hemihypertrophy (41.4%), pre- or postnatal macrosomia
(38.7%), ear creases/pits (36.4%), neonatal hypoglycaemia
(29.8%), facial naevus flammeus (FNF, 24.1%), organome-
galy (17.0%), polyhydramnios (10.1%), maxillary hypopla-
sia (9.6%), congenital heart defects (8.3%), and embryonal
tumours (3.1%). The median number of clinical features at
referral was three (range 1 to 13). Of those with a single
clinical indication (22.8% of total referrals), the most fre-
quent was hemihypertrophy (present in 65.5% of those
with a single feature). In those with two or more clinical
indications for referral, the most frequent combinations of
features were macroglossia and ear creases/pits (37.9%).
Molecular genetic results and relationship to clinical
indications for referral
Overall, 507/1,091 (46.5%) individuals tested had an
abnormal methylation profile at IC1 and/or IC2. Forty-
seven (4.3%) had hypermethylation at IC1 only, 321
(29.4%) had isolated IC2 hypomethylation, and 135 (12.4%)
had abnormal IC1 and IC2 methylation from pUPD.
Of those with an aberrant IC1 methylation profile, three
(0.3%) individuals had a copy number abnormality (all
duplications), while of those who had an aberrant IC2
methylation profile, one (0.1%) individual had a copy
number abnormality (deletion). Thus, among patients
with a positive molecular diagnosis, 63.3% had evidence of
an IC2 epimutation, 26.6% pUPD, 9.3% IC1, and 0.8% had
a copy number abnormality (it should be noted that our
testing was not sensitive to all BWS methylation abnor-
malities: diagnoses due to low-level mosaicism may be
missed [21,22] and some cases with normal BWS methyla-
tion profiles may have CDKN1C mutations [10,15]).
In general, the greater the number of clinical features
of BWS present at referral, the greater the likelihood of
a positive molecular diagnosis. Thus, 79.3% of those with
five or more relevant clinical findings had a positive
diagnostic test, and 65.2%, 45.5%, 26.4% and 12.4% of
those with four, three, two and one clinical indications,
respectively. Of those with isolated hemihypertrophy
and no other clinical features, 12.9% had a positive diag-
nostic test.
Individual clinical features associated with a greater
than average frequency of a positive diagnostic test for
methylation abnormalities were: FNF (73.1%), diastasis
recti (72.4%), organomegaly (72.3%), macroglossia (72.2%),
polyhydramnios (71.6%), and exomphalos (70.0%), whereas
the presence of hemihypertrophy was associated with a
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(Table 1).
Of those with a molecular diagnosis of BWS, 3.4%
(17/507) had an embryonal tumour at referral (mean
age 3.7 years, range 0 to 16 years (precise age data unavail-
able for five individuals)). Eight individuals had Wilms’
tumour (IC1 in four, IC2 in one, pUPD in two, and an
11p15.5 duplication in one individual), six a hepatoblas-
toma (IC2 in one, and pUPD in five individuals), one an
adrenal cortical carcinoma (pUPD), and one a rhabdo-
myosarcoma (IC2). Of these, one individual had both a
Wilms’ tumour and a hepatoblastoma (IC1). Interestingly,
a further 17 mutation negative referrals had embryonal
tumours, with the number of clinical features ranging
from one to nine (median three).
Genotype-phenotype associations
We compared the frequency of different clinical features
of BWS between four molecular subgroups; (a) pUPD,
(b) IC1 hypermethylation, (c) IC2 hypomethylation, and
(d) a normal methylation profile (Figure 1). Significant
intergroup differences amongst those with a positive
molecular diagnosis included increased frequencies of
hemihypertrophy in those with pUPD compared to the
IC1 and IC2 subgroups (72.6% versus 27.7% and 18.7%;
P < 0.001 and P < 0.001, respectively), macroglossia in
the IC2 subgroup (88.2%) compared to pUPD (68.1%;
P < 0.001) and IC1 (70.2%; P = 0.003), FNF in IC2 (44.5%)
vs pUPD (29.6%; P = 0.003) and IC1 (14.9%; P < 0.001), ear
creases/pits in IC2 (61.7%) vs pUPD (34.8%; P < 0.001)
and IC1 (38.3%; P = 0.004), and exomphalos in IC2 (49.2%)Table 1 Distribution of individual Beckwith-Wiedemann synd
pUPD IC1
Facial naevus flammeus 21.1% (40/190) 3.7%
Diastasis recti 33.3% (14/42) 23.8%
Organomegaly 38.3% (51/133) 16.5%
Macroglossia 22.5% (92/408) 8.1%
Polyhydramnios 24.4% (19/78) 3.8%
Exomphalos 6.9% (12/173) 1.7%
Prognathism 22.0% (11/50) 10.0%
Ear creases/pits 17.9% (47/263) 6.8%
Maxillary hypoplasia 29.4% (20/68) 11.8%
Macrosomia 29.7% (80/269) 8.2%
Neonatal hypoglycaemia 28.9% (58/201) 8.5%
Umbilical hernia 33.8% (47/139) 10.8%
Inguinal hernia 18.2% (4/22) 0.0%
Congenital heart defects 18.0% (9/50) 10.0%
Embryonal tumours 43.8% (7/16) 37.5%
Hemihypertrophy 57.3% (98/171) 7.6%
IC1, imprinting centre 1; IC2, imprinting centre 2; pUPD, paternal uniparental disomvs pUPD (8.9%; P < 0.001) and IC1 (6.4%; P < 0.001). Con-
versely, there were reduced frequencies of organome-
galy and embryonal tumours in the IC2 subgroup
(18.7% and 0.9%, respectively) compared to pUPD
(37.8%, P < 0.001; and 5.2%, P = 0.009, respectively) and
IC1 (46.8%, P < 0.001; and 12.8%, P < 0.001, respectively).
Whilst there was a significant increase in the frequency
of umbilical hernias in pUPD (34.8%) in comparison to
IC2 (24.0%; P = 0.021), the differences between IC1 (31.9%)
and IC2 were not statistically significant (P = 0.279). Simi-
larly, for diastasis recti, increased frequencies in the IC1
subgroup (21.3%) relative to IC2 (5.6%; P = 0.001) were evi-
dent, but there were no significant differences between
pUPD (10.4%) and IC2 (P = 0.074). There were no signifi-
cant intergroup differences in frequencies for macrosomia,
neonatal hypoglycaemia, polyhydramnios, prognathism,
maxillary hypoplasia, congenital heart defects, or inguinal
hernias.
Clinical features predictive of positive molecular findings
We investigated which clinical features might have the
best predictive value for a positive diagnostic test for an
abnormal IC1 and/or IC2 methylation. Using logistic re-
gression, a backwards stepwise selection procedure yielded
the following clinical features for inclusion in our scoring
system; macroglossia, exomphalos, organomegaly, macro-
somia, FNF, neonatal hypoglycaemia, and hemihypertro-
phy (Table 2). Since macroglossia and exomphalos had the
highest regression coefficient estimates, appropriately,
these were weighted with the highest scores, whilst neo-
natal hypoglycaemia and hemihypertrophy had the lowestrome clinical features according to molecular subtype
IC2 Total
(7/190) 75.3% (143/190) 73.1% (190/260)
(10/42) 42.9% (18/42) 72.4% (42/58)
(22/133) 45.1% (60/133) 72.3% (133/184)
(33/408) 69.4% (283/408) 72.2% (408/565)
(3/78) 71.8% (56/78) 71.6% (78/109)
(3/173) 91.3% (158/173) 70.0% (173/247)
(5/50) 68.0% (34/50) 67.6% (50/74)
(18/263) 75.3% (198/263) 66.8% (263/394)
(8/68) 58.8% (40/68) 65.4% (68/104)
(22/269) 62.1% (167/269) 64.4% (269/418)
(17/201) 62.7% (126/201) 62.4% (201/322)
(15/139) 55.4% (77/139) 59.9% (139/232)
(0/22) 81.8% (18/22) 59.5% (22/37)
(5/50) 72.0% (36/50) 55.6% (50/90)
(6/16) 18.8% (3/16) 48.5% (16/33)
(13/171) 35.1% (60/171) 38.2% (171/448)
y.
Figure 1 Frequencies of Beckwith-Wiedemann syndrome clinical features according to molecular subtype. (a) Hemihypertrophy, (b)
macroglossia, (c) facial naevus flammeus, (d) ear creases/pits, (e) exomphalos, (f) organomegaly, and (g) embryonal tumours. ALL-MUT, all mutations;
IC1, imprinting centre 1; IC2, imprinting centre 2; NIL, no mutations; pUPD, paternal uniparental disomy.
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molecular abnormality ranges from 7.8% for a score of 0
to 98.2% for a score of 8 (Figure 2).In evaluating the performance of our scoring system,
we used a probability threshold of 0.5 (equating to a
score of 3.06) for a positive molecular diagnosis. Given
Table 2 Logistic regression analysis for the prediction of a Beckwith-Wiedemann syndrome molecular abnormality
Bootstrap statistics
Estimate Bias-corrected estimate OR (95% CI) P
Constant −2.45 −2.47 0.08 (0.06-0.13) <0.001
Macroglossia 2.08 2.10 8.17 (5.70-11.02) <0.001
Exomphalos 1.14 1.15 3.16 (2.07-4.62) <0.001
Organomegaly 0.93 0.94 2.55 (1.64-4.62) <0.001
Macrosomia 0.78 0.79 2.19 (1.58-2.97) <0.001
Facial naevus flammeus 0.74 0.75 2.12 (1.44-3.00) <0.001
Hypoglycaemia 0.40 0.41 1.50 (1.06-2.08) 0.021
Hemihypertrophy 0.40 0.41 1.50 (1.04-2.14) 0.022
OR, odds ratio.
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settled for a minimum score of 3.5 (probability of 0.59).
Thus, our simplified scoring system, with few and easy
to distinguish features, has positive and negative predictive
values of 78.4% and 79.6%, respectively (Table 4). Whilst
the criteria by DeBaun and Tucker [16] had the greatest
sensitivity of 83.5%, this was compounded with the lowest
specificity of 62.3%. Similarly, a specificity of 94.1%
by Gaston et al. [18] (using their complete classifica-
tion of BWS) was paired with the lowest sensitivity of
43.3% in the series. Thus, whilst our new scoring sys-
tem does not have the best sensitivity (75.9%) and
specificity (81.8%), for any given sensitivity it has the
greatest specificity, and for any given specificity the
greatest sensitivity (Figure 3). Indeed, our new model
has the greatest AUC of the ROC curve of 0.85 (95%
CI, 0.83 to 0.87). Moreover, cross-validation of the
model yielded a comparable AUC of 0.84 (95% CI,
0.81 to 0.86).
Discussion
Previously, we and others have reported epigenotype-
phenotype associations in BWS [12,15,19,23-25]. In par-
ticular, molecular subgroups associated with CDKN1CTable 3 Beckwith-Wiedemann syndrome molecular
abnormality outcome score
Score
Macroglossia 2.5
Exomphalos 1.5
Organomegaly 1
Macrosomia 1
Facial naevus flammeus 1
Hemihypertrophy 0.5
Hypoglycaemia 0.5loss of function (CDKN1C mutations and IC2 epimuta-
tions) have a significantly higher frequency of exomphalos
than in patients with pUPD or IC1 epimutations (asso-
ciated with biallelic expression of IGF2), whereas the risk
of Wilms’ tumour is higher in the latter two groups. In
this current study, an analysis of >500 patients with pUPD,
IC1 and IC2 epimutations identified additional potential
genotype-phenotype associations. Thus, isolated IC2 epi-
mutations have a significantly increased association with
macroglossia and FNF, whilst the pUPD and IC1 sub-
groups have a greater association with organomegaly than
in IC2.
We further identified the clinical features that are
most predictive of a positive molecular genetic test for
abnormal methylation at the two 11p15.5 ICs. The most
common molecular abnormality in BWS is loss of ma-
ternal allele methylation at IC2 (found in the 50 to 60%
of cases with IC2 epimutations and in the 20% with
pUPD) followed by gain of maternal allele methylation
at IC1 (found in 5 to 10% of cases with IC1 epimutations
and in the 20% with pUPD) [22]. IC1 and IC2 methy-
lation profiling can also detect copy number abnormal-
ities – most of which are IGF2/H19 duplications and large
scale CDKN1C/IC2 deletions – though each of these
findings is rare [10]. Although patients with germline
CDKN1C mutations will not be detected, these are infre-
quent in sporadic cases, and only about 15% of BWS
patients have a positive family history [10,15]. It should
also be noted that pUPD is usually mosaic (and IC1 and
IC2 epimutations commonly are) and low level mosaicism
might not be detected by some methods of methylation
analysis [21]. Hence, a normal ‘BWS methylation assay’
does not necessarily exclude a diagnosis of BWS - though
it may be useful in prioritising further investigations. Thus
a ‘BWS methylation assay’ is well established as the initial
investigation of choice for potential cases and, if negative,
then further investigations are generally only initiated in
selected cases (for example, CDKN1C mutation analysis in
Figure 2 Predicted and observed probabilities for a Beckwith-Wiedemann syndrome methylation abnormality based on the new scoring
system. methylation abnormalityð Þ ¼ e‐2:47þ 0:808
P
scoresð Þ
1 þ e‐2:47þ 0:808
P
scoresð Þ .
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features of macroglossia and exomphalos) [10,25].
As genetic testing becomes less expensive and more
accessible, testing is frequently requested by non-specialist
clinicians, and it becomes increasingly useful to have cri-
teria for identifying those patients who are most likely to
have a positive test. Traditionally, clinical diagnostic cri-
teria are used to select patients for molecular investiga-
tions. However, in the case of BWS clinical diagnostic
criteria might be satisfied but molecular testing might be
negative and, conversely, a molecular abnormality might
be detected in a patient who does not satisfy clinical diag-
nostic criteria – such as in isolated hemihypertrophy.
Here, we have focused on identifying a set of clinical
criteria that are most predictive of a positive ‘BWS
methylation assay’. Initially, we evaluated different sets of
proposed clinical diagnostic criteria and, although someTable 4 Scoring outcomes of different Beckwith-Wiedemann
Sensitivity Specificity
New scoring system† 75.9% 81.8%
Elliott et al. [17] 43.5% 93.9%
DeBaun and Tucker [16] 83.5% 62.3%
Weksberg et al. [19] 74.4% 75.4%
Zarate et al. [20] 69.8% 82.5%
Gaston et al. [18]‡ 43.3% 94.1%
†Probability threshold of 0.5 (outcome score ≥3.5) was used for a positive molecula
used (see Table 5).performed better than others, none was strikingly super-
ior. We therefore used logistical regression analysis to
identify those features most predictive of a positive ‘BWS
methylation assay’ test and then developed a weighted
clinical scoring system that was demonstrated to outper-
form previously reported sets of clinical diagnostic criteria
[16-20]. Hence, we propose that this new scoring system
should be used to guide which individuals with suspected
BWS should be selected for investigation with a ‘BWS
methylation assay’ test. However, it should be noted that
there are limitations to this scoring system. Firstly, less
frequent, but potentially significant, clinical features such
as embryonal tumours are not incorporated into the scor-
ing system because there is insufficient data to support
their inclusion, and so the scoring system would not be
appropriate for patients presenting with a BWS-related
tumour. Secondly, the scoring system is to predict asyndrome clinical diagnostic criteria
Positive predictive value Negative predictive value
78.4% 79.6%
86.2% 65.7%
65.8% 81.3%
72.5% 77.2%
77.7% 75.8%
86.5% 65.6%
r diagnosis. ‡Complete classification of Beckwith-Wiedemann syndrome was
Figure 3 Receiver operating characteristic curves comparing
the proposed new scoring system against existing clinical
diagnostic criteria for a positive Beckwith-Wiedemann syn-
drome methylation abnormality. †Complete classification of
Beckwith-Wiedemann syndrome was used (see Table 5).
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positive result for all BWS-associated molecular abnormal-
ities. Thus, in familial BWS, where CDKN1C mutations
are the most frequent abnormality [22], a scoring system
designed to predict an abnormal ‘BWS methylation assay’
would not be appropriate as a normal IC1/2 methylation
profile and a positive family history of maternally inherited
BWS would indicate a requirement for CDKN1C mutation
analysis [25]. Similarly, this is also indicated in sporadic
cases with an abdominal wall defect (umbilical hernia or
exomphalos) and no hemihypertrophy. Although our co-
hort was not comprehensively tested for CDKN1C
mutations, 2.9% (17/584) of referrals with a normal ‘BWS
methylation assay’ result were later found to have a
CDKN1C mutation (mean score 4.1, range 0 to 7).
Furthermore, the challenge that detection of low-level
mosaicism brings to BWS diagnostics must be consid-
ered [21]. Thus, given the increased risk of tumorigen-
esis in individuals with isolated hemihypertrophy [26], and
the difficulty in identifying a molecular abnormality, such
individuals may benefit from further sensitive testing [21].
Although our scoring system focuses on improving the
diagnostic rate of BWS, in comparison to current clinical
diagnostic criteria, for any given sensitivity it has the
highest specificity and vice versa, thus improving the
overall diagnosis of the disorder. Moreover, in view of
the tumour risk to a missed diagnosis of BWS, a mole-
cular diagnostic or specialist genetic referral may still bewarranted in individuals with borderline scores (3.0).
Indeed, as testing becomes increasingly less expensive,
the probability threshold for a BWS methylation ab-
normality can be reduced in order to improve overall
diagnosis at the cost of a less-specific scoring system.
Nevertheless, multicentre studies of even larger datasets
will enable further refinement of our scoring system – in
particular the incorporation of rarer clinical features that
would increase the prior probability of BWS (for example,
positive family history, history of assisted reproductive
technology conception, and embryonal tumours) and also
allow bespoke predictions for specific BWS molecular
subtypes.Conclusions
In summary, we suggest that this novel tool will facilitate
selection of patients with suspected BWS for routine
diagnostic testing and so improve the diagnosis of the
disorder.
Methods
Patients
We systematically collected clinical and molecular data
on children and adults with suspected BWS referred to a
molecular diagnostic testing service between April 2003
and October 2013. Clinical data were collected by a
standardised questionnaire completed by the clinician
who ordered the molecular assay and by inspecting
clinical notes. Not all the clinical data requested was
available, which is reflected by the variable number of
clinical features. Consent for diagnostic testing was
provided by the patient or by the parent/guardian for
children. The collection of clinical and molecular data
to evaluate the diagnostic testing service was approved by
the Birmingham Women’s Hospital Research and Devel-
opment Office.
Methylation studies
DNA was isolated from peripheral blood lymphocytes
or tissue samples by standard procedures. Methylation
analysis was performed in the West Midlands Regional
Molecular Genetics Laboratory using a methylation-sensi-
tive multiplex ligation-dependent probe amplification
(MS-MLPA) kit (SALSA MLPA kit ME030; MRC-Holland,
Amsterdam, The Netherlands) and/or pyrosequencing,
with both methods giving comparable results [10,27].
A categorisation of a normal or an abnormal methylation
analysis assay result was made according to the clinical
diagnostic report issued by the laboratory. Analysis of the
MS-MLPA data was performed using the GeneMarker
v1.70 (SoftGenetics, Pennsylvania, USA) software such
that the ratio of normalised peak intensities was compared
between the reference and the sample trace; ratios of
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probes (four at IC1 and four at IC2) was taken to indicate
loss or gain of methylation, respectively. Pyrosequencing
results were analysed using the PyroMark ID (Qiagen,
Venlo, The Netherlands) software (using ‘allele quantifica-
tion mode’) to calculate an average methylation value for
the seven CpG sites in the IC2 assay and the four CpG
sites in the IC1 assay. A cohort of 89 normal controls was
used to calculate the average methylation index (MI) for
each of the assays, and patients with a MI greater than or
less than three standard deviations from the mean of
normal controls were categorised as hyper- or hypomethy-
lated, respectively. The presence or absence of pUPD was
confirmed by microsatellite analysis using markers that
mapped to 11p15.5 [28]. Equivocal results were excluded
from the analysis.Statistics
We utilised logistic regression in order to determine the
predictive power for a positive methylation assay test of
current BWS clinical diagnostic criteria (Table 5). We de-
veloped our own model using stepwise logistic regressionTable 5 Published clinical diagnostic criteria for Beckwith-Wie
Elliott et al. [17] DeBaun and Tucker [16]
Major features Abdominal wall
defect
Abdominal wall defect
Macroglossia Ear creases/pits
Macrosomia Hypoglycaemia
Macroglossia
Macrosomia
Minor features Ear creases/pits Nil
Facial naevus
flammeus
Hemihypertrophy
Hypoglycaemia
Nephromegaly
Clinical diagnosis
of Beckwith-Wiedemann
syndrome
At least three major
features, or two
major features plus
three or more
minor features
At least two major featuresfor variable selection [29], with the BWS MS-MLPA result
as the dependent variable. Using backwards selection, we
eliminated statistically insignificant predictors to arrive at
a final parsimonious model. Bootstrap resampling was
performed in order to arrive at bias-corrected regression
coefficients, odds ratios, and 95% CIs; 100,000 samples
were drawn with replacement so as to arrive at stable
estimates [30]. A weighted scoring system was devised
according to the regression coefficients, and predictions of
methylation abnormalities based upon the sum of the
scores calculated using a simple logistic regression. Re-
ceiver operating characteristic (ROC) curves were used to
determine the accuracy of our new model and current
diagnostic criteria, and were quantified with respect to the
area under the ROC curve (AUC). In the new model, a
probability threshold of 0.5 was used for a positive mo-
lecular diagnosis. We validated our model using a 10-fold
cross-validation procedure [29]. Fisher’s exact testing was
used as appropriate. All tests of significance were two-
sided and we used a statistical significance threshold
of P = 0.05. Data were analysed using statistical packages
R v3.0.2 (http://www.r-project.org/) and SPSS v20 (SPSS
Inc., Chicago, Illinois, USA).demann syndrome
Weksberg et al. [19] Zarate et al. [20] Gaston et al. [18]
Abdominal wall
defect
Abdominal wall defect Abdominal wall defect
Ear creases/pits Macroglossia Macroglossia
Embryonal tumours Macrosomia Macrosomia
OrganomegalyHemihypertrophy
Macroglossia
Macrosomia
Hypoglycaemia Cardiomegaly Ear creases/pits
Organomegaly Ear creases/pits Facial naevus
flammeus
Hemihypertrophy
Hypoglycaemia
Renal malformation Facial naevus flammeus
Hemihypertrophy
Hypoglycaemia
Mid-face hypoplasia
Polyhydramnios
At least three major
features, or two major
features and one or
more minor features
At least three major
features, or two major
features and one or
more minor features
Complete and
incomplete Beckwith-
Wiedemann syndrome
classification.
Complete – at least
three major features.
Incomplete – less than
three major features
and one or more minor
features
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